PT-141 Guide & Dosage Chart

What is PT-141?

PT-141 is the research name for a synthetic peptide called bremelanotide. It was originally developed by Palatin Technologies as a potential treatment for sexual dysfunction in both men and women.^[1] Unlike older approaches to sexual health — think blood-flow drugs — PT-141 works directly in the brain rather than on blood vessels. That makes it a genuinely different kind of compound to study.

Bremelanotide is a synthetic analogue of a natural hormone called alpha-melanocyte-stimulating hormone (α-MSH). That just means scientists took the natural hormone and tweaked its structure to make it more stable and effective.^[5] The result is a cyclic peptide with a molecular weight of about 1,025 daltons.^[4]

How PT-141 Works

Think of the brain's sexual-response system like a see-saw. On one side you have signals that excite sexual desire; on the other, signals that inhibit it. Research suggests that disorders like low sexual desire may involve that see-saw tipping too far toward inhibition.^[6]

PT-141 acts as an agonist — basically a key that fits into and activates — a brain receptor called the melanocortin type 4 receptor (MC4R). This receptor is thought to play an important role in sexual function. By activating it, PT-141 is believed to nudge brain pathways involved in sexual response toward the excitation side of that see-saw.^[5] It's a central, brain-based mechanism, which is what makes it stand out in this area of research.

What the Research Shows

Early research positioned PT-141 as a nasal spray candidate for both erectile dysfunction and female sexual dysfunction, with Phase IIb trials in erectile dysfunction completed by late 2003.^[1] The science has evolved considerably since then.

The compound eventually moved to subcutaneous (under-the-skin) injection, and its development focused on hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as a persistent lack of sexual thoughts or desire that causes real personal distress and has lasted at least six months — and it's actually the most commonly identified sexual problem among women.^[6]

Bremelanotide is now described in the medical literature as one of only two pharmacologic agents specifically studied and approved for generalized acquired HSDD in premenopausal women, alongside flibanserin.^[2] Both are classified as psychoactive agents because they target brain pathways rather than peripheral tissue.^[2]

On the safety side, research has noted that bremelanotide can cause mild elevations in liver enzymes during use, and rare cases of clinically apparent acute liver injury have been reported.^[3] Nausea is a commonly noted side effect in studies. These findings are part of why careful monitoring is important in any research context.

What PT-141 Is Being Studied For

• Hypoactive sexual desire disorder (HSDD) in premenopausal women — the primary and most-studied application.^[5]
• Female sexual dysfunction (FSD) more broadly — researchers are exploring its role within the wider spectrum of overlapping sexual disorders.^[2]
• Sexual dysfunction in men — early-stage work examined its potential for erectile dysfunction, though later research concentrated on women.^[1]

It's worth noting: PT-141 is a research compound. Everything on this page is for educational and scientific reference only. It is not medical advice, and this compound should not be used for personal self-treatment.

How PT-141 Is Dosed in Research

Dosing in research contexts follows the protocols established in clinical studies. The most well-documented regimen — used in studies of HSDD in premenopausal women — involves subcutaneous administration on an as-needed basis.^[5] Researchers typically observe strict limits on frequency to minimize side effects. Full details, including specific amounts and timing windows studied in clinical trials, are laid out in the dosage chart on this page. If you're working with dosage calculations, the calculator on this page can help with the math. Always cross-reference any protocol against the primary literature before use in a research setting.

Mixing and Storing PT-141

PT-141 is a peptide, which means it comes as a delicate powder that must be handled carefully. Here are the basics researchers follow:

• Reconstitution: The lyophilized (freeze-dried) powder is typically dissolved using bacteriostatic water. Add the water slowly down the side of the vial — don't shake it. Swirl gently until fully dissolved.
• Storage before mixing: Keep the dry powder refrigerated (around 2–8 °C / 36–46 °F) and away from light. Some protocols allow short-term storage at room temperature, but cold storage preserves stability longer.
• Storage after mixing: Once reconstituted, store in the refrigerator and use within the timeframe recommended by your supplier or protocol — typically within a few weeks. Do not freeze reconstituted peptide.
• Handling: Use sterile technique throughout. Peptides like bremelanotide are cyclic structures,^[4] which gives them more stability than linear peptides, but they can still degrade with heat, light, or repeated freeze-thaw cycles.
• Never use if: the solution looks cloudy, discolored, or contains particles.

Sources

1. PT-141 Palatin. — Current opinion in investigational drugs (London, England : 2000), 2004. PMID 15134289.
2. Medical Treatment of Female Sexual Dysfunction. — The Urologic clinics of North America, 2022. PMID 35428435.
3. Bremelanotide. — , 2012. PMID 34436837.
4. Bremelanotide. — , 2006. PMID 31369224.
5. Bremelanotide: First Approval. — Drugs, 2019. PMID 31429064.
6. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. — Journal of midwifery & women's health, 2021. PMID 34510696.